Syfovre claims for vision loss and blindness involving retinal vasculitis diagnosed after a patient’s first Syfovre injection are being filed as drug injury lawsuits. The basis for these product liability Syfovre lawsuits is the drug company Apellis Pharmaceuticals failed to warn about retinal vasculitis as a side effect until it revised the … [Read more...]
Syfovre’s Side Effects Keep It Off The Market In Europe (CHMP June 2024)
As we have been reporting since July 2023, Syfovre’s side effects include occlusive retinal vasculitis, a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and potentially causing blindness. There have also been cases of non-occlusive retinal vasculitis and other types of eye inflammation. In late June 2024, … [Read more...]
Syfovre: Eye Problems After Injection of Syfovre (pegcetacoplan)
This blog post is about a 78-year-old woman with Syfovre eye problems involving vision loss in the first part of 2023. This Syfovre side effects case was reported in “Retinal vasculitis following intravitreal pegcetacoplan administration”, a medical journal article that appeared in the March 2024 edition of the American Journal of Ophthalmology … [Read more...]
Syfovre Eye Injury Cases Update One Year After First Reports: “Uncertain”
Beginning in April 2023, there have been reports of Syfovre eye injury cases, including retinal vasculitis resulting in significant vision loss. As of the beginning of April 2024, however, retina specialists seem to agree that both the etiology and the incidence rate of retinal vasculitis after Syfovre injections remain uncertain. Put in more … [Read more...]
Syfovre Eye Injuries Decreased Vision For Patients After Syfovre Treatments
Members of the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee recently issued a general report on cases where Syfovre eye injuries decreased vision for patients after Syfovre treatments. In summary, this report revealed that at least 13 patients had Syfovre retinal-related vision loss in … [Read more...]
New Syfovre Warnings for Retinal Vascular Occlusion and Retinal Vasculitis
A November 2023 label change added new Syfovre warnings for retinal vascular occlusion and retinal vasculitis cases associated with Syfovre injections. With these new Syfovre warnings, it now seems that the retinal vascular occlusion and retinal vasculitis cases associated with Syfovre use are due to the drug itself and not the injection kits, as … [Read more...]
Retinal Vasculitis Cases Caused by Syfovre Injection Kits With a 19-gauge Filter Needle?
In what seems to be the latest Syfovre safety update, in early October 2023 Apellis reported an increase in the number of Syfovre retinal vasculitis cases, but Apellis did not provide any significant new information regarding an “explanation” as to how certain Syfovre injection kits might have caused these adverse reaction events. EndPoints News … [Read more...]
Syfovre Eye Injections Adverse Reactions Update August 2023
We have some new information about Syfovre eye injections adverse reactions causing vision loss and blindness from Apellis Pharmaceuticals and the American Society of Retina Specialists (ASRS). Apellis Pharmaceuticals said that it has confirmed seven cases of Syfovre eye injections adverse reactions. More specifically, these Syfovre vision loss … [Read more...]
Syfovre Retinal Vasculitis Cases Warning Letter July 2023
The American Society of Retinal Specialists (ASRS) issued a warning letter about the Syfovre retinal vasculitis cases in patients who used this injection eye drug. Syfovre is a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Occlusive retinal vasculitis is a type of eye inflammation that blocks blood flow … [Read more...]
Beovu Label Change: Novartis Adds Information, Increases Safety Warnings in February 2022
We had been watching for a second Beovu label change since May 2021, when Novartis stopped three Beovu clinical trials for safety reasons, and, at the same time, said it would update the Beovu drug label. Finally, in February 2022, Novartis added information and increased safety warnings about various Beovu eye-related side effects, such as retinal … [Read more...]